880432--9/28/2010--MISONIX

related topics

{property, intellectual, protect}

{product, candidate, development}

{regulation, change, law}

{product, market, service}

{financial, litigation, operation}

{customer, product, revenue}

{acquisition, growth, future}

{stock, price, operating}

{regulation, government, change}

{personnel, key, retain}

{capital, credit, financial}

{cost, operation, labor}

{product, liability, claim}

We may not meet regulatory quality standards applicable to our manufacturing and quality processes, which could have an adverse effect on our business, financial condition or results of operations. Future intellectual property litigation could be costly and disruptive to us. We may not be able to effectively protect our intellectual property rights. Future product liability claims and other litigation, including private securities litigation and shareholder derivative suits, may adversely affect our business, reputation and ability to attract and retain customers. We may not be successful in our strategic initiatives to become primarily a medical device company. Our future growth is dependent upon the development of new products, which requires significant research and development, clinical trials and regulatory approvals, all of which are very expensive and time-consuming and may not result in a commercially viable product. New products may not be accepted in the market. We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations. Consolidation in the healthcare industry could lead to demands for price concessions or the exclusion of some suppliers from certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations. We may experience disruption in supply due to our dependence on our suppliers to continue to ship product requirements and our inability to obtain suppliers of certain components for our products. If we fail to manage any expansion or acquisition, our business could be impaired. Our agreements and contracts entered into with partners and other third parties may not be successful. The current disruptions in the financial markets could affect our ability to obtain debt financing on favorable terms (or at all) and have other adverse effects on us. The fluctuation of our quarterly results may adversely affect the trading price of our common stock. We may not be able to attract and retain additional key management, sales and marketing and technical personnel, or we may lose existing key management, sales and marketing or technical personnel, which may delay our development and marketing efforts. Future changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse or unexpected revenue fluctuations and affect our reported results of operations. Adverse litigation results could affect our business. The recently enacted Affordable Healthcare for America Act includes provisions that may adversely affect our business and results of operations, including an excise tax on the sales of most medical devices.

Full 10-K form ▸

880432--9/28/2010--MISONIX_INC